skip to the content

ABPI Code Reporting

Roche aims to ensure all our work and activities are delivered to the highest ethical standards and is fully committed to the appropriate use of medicines and protecting the safety of patients.

Roche is also fully committed to, and accountable for, working within the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice.

The ABPI is the trade association for the pharmaceutical industry in the UK.

The Code of Practice for the Pharmaceutical Industry regulates the advertising of medicines for prescription to health professionals and administrative staff and also covers information about prescription only medicines made available to the general public.

The pharmaceutical industry recognises and supports transparency as an important means of building and maintaining confidence and trust with the general public, and of demonstrating the integrity of our interactions and relationships with healthcare professionals (HCPs), healthcare organisations and patient organisations.

To support this drive for increased transparency the ABPI Code of Practice requires all companies to disclose: summary details and results of non-interventional studies, details of monetary grants or donations made to institutions or organisations, HCP sponsorship for third party events, payments made to UK consultants, details of the monetary value of certain support to patient organisations, a list of patient organisations that provide consultancy services and details of any so called Joint Working initiatives between a pharmaceutical company and the NHS.

Roche Products LTD and Chugai Pharma UK LTD have a co-promotion agreement in place for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements each company will independently disclose payments associated with this co-promotion. To view Chugai Pharma Ltd (Roche Products Ltd) payments please click on this link.